IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
July 25 2024 - 4:05PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform, announced today that an
abstract related to IO102-IO103, the company’s lead investigational
therapeutic cancer vaccine candidate, has been accepted for poster
presentation at the European Society for Medical Oncology (ESMO)
Congress 2024. The poster will share data from one of the Phase 2
basket trials of IO102-IO103 in combination with pembrolizumab
(KEYTRUDA®), Merck’s anti-PD-1 therapy. The data for the complete
squamous cell carcinoma of the head and neck (SCCHN) cohort of the
IOB-022/KN-D38 study will be presented at the Congress, which takes
place in Barcelona from September 13-17, 2024.
“This completed cohort data marks a significant
step forward in our efforts to explore the potential of IO102-IO103
as a therapeutic cancer vaccine across a range of solid tumors
where there is a high need for new, accessible treatments,” said
Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “We look
forward to the presentation of this data at the upcoming ESMO
Congress and the continued development of our novel
immune-modulating cancer vaccine that could potentially improve
outcomes for people living with cancer.”
Presentation Details
Title: A phase 2 trial of the
IO102-IO103 vaccine plus pembrolizumab: completed cohort for first
line (1L) treatment of advanced Squamous Cell Carcinoma of the Head
and Neck (SCCHN)Presentation date: Saturday, September 14,
2024Presenter: Jonathan W. Riess, MD MS (UC Davis Comprehensive
Cancer Center)Presentation number: 1022P
The poster will be available on the “Posters
& Publications” page of the IO Biotech website at the start of
the meeting.
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf
therapeutic cancer vaccine designed to kill both tumor cells and
immune-suppressive cells in the tumor microenvironment (TME) by
stimulating activation and expansion of T cells against indoleamine
2,3-dioxygenase (IDO) positive and/or programmed death-ligand 1
(PD-L1) positive cells. The company is currently conducting a
pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating
IO102-IO103 in combination with pembrolizumab versus pembrolizumab
alone in patients with advanced melanoma, a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in
combination with pembrolizumab as first line treatment in patients
with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40;
NCT05280314) investigating IO102-IO103 in combination with
pembrolizumab as neo-adjuvant/adjuvant treatment of patients with
solid tumors.
The clinical trials are sponsored by IO Biotech
and conducted in collaboration with Merck, which is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About IOB-022/KN-D38 Phase 2 Solid Tumor
Basket Trial
IOB-022/KN-D38 (NCT05077709) is a
non-comparative, open label trial to investigate the safety and
efficacy of IO102-IO103 in combination with pembrolizumab in
first-line advanced cancers in non-small cell lung cancer (NSCLC)
and squamous cell carcinoma of the head and neck (SCCHN). IO
Biotech is sponsoring the Phase 2 trial and Merck is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform. The T-win platform is based
on a novel approach to cancer vaccines designed to activate T cells
to target the immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing its lead cancer vaccine
candidate, IO102-IO103, in clinical trials, and additional pipeline
candidates through preclinical development. Based on positive Phase
1/2 first line metastatic melanoma data, IO102-IO103, in
combination with pembrolizumab, has been granted a breakthrough
therapy designation for the treatment of advanced melanoma by the
US Food and Drug Administration. IO Biotech is headquartered in
Copenhagen, Denmark and has US headquarters in New York, New
York.
For further information, please visit
www.iobiotech.com. Follow us on our social media channels on
LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the primary analysis of the company’s Phase
3 trial, current or future clinical trials, their progress,
enrollment or results, timing of submission of marketing
applications, or the company’s financial position or cash runway,
are based on IO Biotech’s current assumptions and expectations of
future events and trends, which affect or may affect its business,
strategy, operations or financial performance, and actual results
and other events may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Nov 2024 to Dec 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Dec 2023 to Dec 2024